Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: Randomized controlled trial evaluating survival, morbidity, and mortality

Annals of Surgery

Volumn 236, Issue 3, 2002, Pages 355-368

  Yeo, Charles J ^a,b   Cameron, John L ^a   Lillemoe, Keith D ^a   Sohn, Taylor A ^a   Campbell, Kurtis A ^a   Sauter, Patricia K ^a   Coleman, JoAnn ^a   Abrams, Ross A ^a   Hruban, Ralph H ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; BLEEDING; CANCER SIZE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; FROZEN SECTION; GASTRECTOMY; HUMAN; LENGTH OF STAY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OPERATION DURATION; PANCREAS CARCINOMA; PANCREAS FISTULA; PANCREATICODUODENECTOMY; PARAAORTIC LYMPH NODE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH EMPTYING; SURGICAL MORTALITY; SURVIVAL TIME; TUMOR LOCALIZATION;

ADENOCARCINOMA; AGED; AMPULLA OF VATER; COMMON BILE DUCT NEOPLASMS; FEMALE; GASTRECTOMY; HUMANS; LYMPH NODE EXCISION; MALE; MIDDLE AGED; PANCREATIC DUCTS; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; PROSPECTIVE STUDIES; RETROPERITONEAL SPACE; SURVIVAL RATE;

EID: 18544365651     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000658-200209000-00012     Document Type: Conference Paper

References (47)

1. Prognostic indicators for survival after resection of pancreatic adenocarcinoma
2. Periampullary adenocarcinoma: Analysis of 5-year survivors
3. Significance of lymph node metastases in patients with pancreatic cancer undergoing curative resection
4. Long-term survival after curative resection of pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors
5. Review topic: Prognostic factors in ductal pancreatic cancer
6. Cholangiocarcinoma: A spectrum of intrahepatic, perihilar and distal tumors
7. Resected adenocarcinoma of the pancreas-616 patients: Results, outcomes, and prognostic indicators
8. DNA content and other factors associated with ten-year survival after resection of pancreatic carcinoma
9. The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma
10. Prediction of recurrence and survival by post-resection CA19-9 values in patients with adenocarcinoma of the pancreas
11. Pancreaticoduodenectomy for pancreatic adenocarcinoma: Postoperative adjuvant chemoradiation improves survival. A prospective, single institution experience
12. Interferon-based adjuvant chemoradiation therapy improves survival after pancreaticoduodenectomy for pancreatic adenocarcinoma
13. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: Phase III trial of the EORTC gastrointestinal tract cancer cooperative group
14. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: A randomized controlled trial
15. Regional resection of cancer of the pancreas: A new surgical approach
16. Recent advances in pancreatic cancer
17. Regional pancreatectomy: En bloc pancreatic, portal vein and lymph node resection
18. Tumor size is the primary prognosticator for pancreatic cancer after regional pancreatectomy
19. 1 carcinoma of the pancreas
20. Surgical strategy for carcinoma of the pancreas head area based on clinicopathologic analysis of nodal involvement and plexus invasion
21. Radical pancreatectomy for ductal cell carcinoma of the head of the pancreas
22. Ductal adenocarcinoma of the pancreas head: Survival after regional versus extended lymphadenectomy
23. Standard versus extended lymphadenectomy associated with pancreaticoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas. A multicenter, prospective, randomized study
24. Pancreaticoduodenectomy with or without extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma: Comparison of morbidity and mortality and short-term outcome
25. The Johns Hopkins experience with pancreaticoduodenectomy with or without extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma
26. Erythromycin accelerates gastric emptying following pancreaticoduodenectomy: A prospective, randomized placebo-controlled trial
27. Does prophylactic octreotide really decrease the rates of pancreatic fistula and other complications following pancreaticoduodenectomy? Results of a prospective randomized placebo-controlled trial
28. Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: Survival results and observations regarding patterns of failure, radiotherapy dose and CA 19-9 levels
29. Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: Acceptable toxicity and improved 1-year disease-free survival
30. A phase I trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GMCSF gene for the treatment of pancreatic adenocarcinoma
31. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: A phase I trial of safety and immune activation
32. Standard versus radical pancreaticoduodenectomy for periampullary adenocarcinoma: A prospective randomized trial evaluating quality of life in pancreaticoduodenectomy survivors
33. Extended lymphadenectomy during pancreaticoduodenectomy for cancer of the pancreas: Summary of "How I Do It" Session
34. Surgery for ductal adenocarcinoma of the pancreatic head: Staging, complications, and survival after regional versus extended lymphadenectomy
35. Randomized prospective trial of pylorus-preserving vs. classic duodenopancreatectomy (Whipple procedure): Initial clinical results
36. 2 gastrectomy for gastric carcinoma
37. 3 total gastrectomy for antral cancer
38. Extended lymph-node dissection for gastric cancer
39. 2 resections for gastric cancer: Long-term results of the MRC randomized surgical trial
40. Letter to the editor
41. The molecular genetics of pancreatic ductal carcinoma: A review
42. Loss of expression of DPC4 in pancreatic intraepithelial neoplasia: Evidence that DPC4 inactivation occurs late in neoplastic progression
43. Discovery of novel tumor markers of pancreatic cancer using global gene expression technology
44. Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated-protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology
45. Prevention of pancreatic cancer and strategies for management of familial pancreatic cancer
46. Physical activity, obesity, height, and the risk of pancreatic cancer
47. Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer